Related Experiment Video
Updated: Jan 24, 2026
07:05
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
9.3K
Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors
Raffaele Di Francia1, Massimiliano Berretta2, Giulio Benincasa3
1Gruppo Oncologico Ricercatori Italiani GORI, 33100 Pordenone, Italy. rdifrancia@libero.it.
Cells
|June 2, 2019
Summary
Cancer patients using angiogenesis inhibitors (AIs) should be cautious with nutraceuticals/dietary supplements (N/DSs). Co-administration can lead to negative interactions, particularly through shared metabolic pathways like cytochrome P450.
Area of Science:
- Oncology
- Pharmacology
- Nutritional Science
Background:
- Angiogenesis inhibitors (AIs) are established cancer treatments.
- Interactions between AIs and antineoplastic drugs are well-studied.
- The impact of nutraceuticals/dietary supplements (N/DSs) on AI efficacy is poorly understood.
Purpose of the Study:
- To review metabolic routes of major AIs and their potential interactions with N/DSs.
- To identify N/DSs that may negatively influence AI treatment.
- To provide a guide for preventing occult AI-N/DS interactions.
Main Methods:
- Comprehensive literature search of PubMed and Cochrane databases.
- Focus on studies detailing metabolic pathways of AIs and N/DSs.
- Compilation of a diagnostic table of known and expected interactions.
Main Results:
- Identified 133 relevant studies.
- Established that AIs and N/DSs sharing cytochrome P450 pathways risk negative interactions.
- Developed a table to guide AI-N/DS interaction assessment.
Conclusions:
- Pharmacogenetics offers tools for personalized AI treatment and identifying predictive markers.
- The developed table aids in genotyping patients to prevent adverse interactions.
- N/DS use in cancer patients on AIs requires urgent scientific attention.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
01:10Mechanism of Angiogenesis
6.7K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.7K
01:24Regulation of Angiogenesis and Blood Supply
3.4K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
616
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
616
02:39Predator-Prey Interactions
21.2K
Predators consume prey for energy. Predators that acquire prey and prey that avoid predation both increase their chances of survival and reproduction (i.e., fitness). Routine predator-prey interactions elicit mutual adaptations that improve predator offenses, such as claws, teeth, and speed, as well as prey defenses, including crypsis, aposematism, and mimicry. Thus, predator-prey interactions resemble an evolutionary arms race.
21.2K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K